Celonic AG, a global biologics development and manufacturing services provider, has completed the acquisition of Glycotope’s bio-manufacturing facility in Heidelberg, Germany. The acquisition expands Celonic’s position in the high-growth CDMO market, with innovative technology platforms and expanded GMP manufacturing assets and capacity for late-stage and commercial supply. Dr. Konstantin Matentzoglu, Celonic’s chief executive officer, said, “With on-boarding of almost two deca...